|
Low brain activity linked to protein levels in
disorder
Fragile X syndrome is marked by autism-like
symptoms
By CZERNE M. REID
People with fragile X syndrome, the most common inherited
developmental disability, have reduced blood levels of a protein vital
for brain development and function, researchers at the School of Medicine
have found. These lowered levels are linked to abnormal activity patterns
in the brain.
“It is exciting to think that a biological marker we can measure
in the blood is correlated with vital brain function,” said Allan
Reiss, MD, professor and director of the Stanford Psychiatry Neuroimaging
Laboratory and Behavioral Neurogenetics Research Center in the Department
of Psychiatry and Behavioral Sciences and the study's senior author.

These sets of images
show brain regions where there was significant activation during the “response
inhibition” tasks used to compare activity in fragile X brains (blue)
with typically developing brains (red). Photo:
Courtesy of Vinod Menon
Additionally, in people with fragile X syndrome, researchers found that
background brain activity outside the realm of problem solving does not
decrease as expected when the individual is confronted with a complex
task. In unaffected people, the brain smoothly redirects resources to
other tasks as needed. This may explain why people with fragile X can't
produce cognitive resources when needed.
The findings, published March 1 in the Proceedings of the National
Academy of Sciences, will enable a more targeted approach to the
development of treatments for the disorder.
Fragile X syndrome is so named because it results from a mutation of a
gene at a “fragile site” on the X chromosome where structural
gaps may occur. It affects roughly 1 in 3,600 males and 1 in 4,000 to
6,000 females, according to the National Fragile X Foundation.
The mutation arises when a repetitive DNA segment of a gene known as FMR1
expands up to hundreds or thousands of times. The FMR1 gene normally produces
fragile X mental retardation protein, which regulates the production of
other proteins controlling how nerve synapses grow and change in response
to learning.
Males with fragile X syndrome produce little or no fragile X protein.
They also have severe manifestations of the disease, including autistic-like
behaviors, hyperactivity and mental retardation. Affected females often
have less extreme symptoms such as attention deficit, shyness, anxiety
and learning problems, although some may show autistic behavior and mental
retardation.
Such a broad spectrum of severity in females corresponds to a wide range
of brain activation patterns and blood levels of fragile X protein. This
range makes females particularly fitting subjects for studying the association
between the protein levels and brain activity in individuals with fragile
X syndrome.
“The effect of genetic factors on brain function is a topic of increasing
interest within the field of cognitive neuroscience, and fragile X syndrome
provides an excellent model to investigate the effect of a single gene
on human brain function” said first author Vinod Menon, PhD, associate
professor of psychiatry and behavioral sciences and a member of Stanford's
neurosciences program.
Menon, Reiss and colleagues examined whether reductions in brain activation
are correlated with levels of fragile X mental retardation protein in
the blood. In previous studies the researchers had shown that individuals
with performance deficits had reduced brain activity in regions known
to be associated with the tasks being performed. They conducted the current
study to shed light on whether the reduced brain activity observed was
simply a function of poor performance or the result of faulty neural processing.
The study, funded by the National Institutes of Health with support from
the Canel Family Fund, observed 18 females ages 10-22 who had the gene
mutation that causes fragile X syndrome, and for comparison, 16 typically
developing age-matched females. Study subjects performed a series of tasks
while undergoing an MRI that allows researchers to monitor brain activity.
The method tracks changes in blood oxygen levels as a marker for changes
in blood flow that, in turn, are closely correlated to nerve cell activity
in the brain.
The so-called response inhibition task researchers used was simple, addressing
the ability to control impulsive behavior. Subjects were shown different
letters of the alphabet that flashed one at a time on a computer screen.
They were asked to respond by pressing a key in every case except when
they saw the letter X. The first task was a “Go” task, in
which the letter X never appeared and in this way subjects were allowed
to build up a tendency to respond. Immediately afterward, subjects performed
a “Go/No Go” task in which the letter X did appear in the
lineup, at which point the subject had to control the previously built
impulse to respond. Statistical correlations were made between observed
reduction in brain activity compared with typically developing individuals
and the levels of fragile X mental retardation protein found in blood
samples taken from each subject.
Individuals with fragile X syndrome performed the response inhibition
task as well as normally developing people, so the observed differences
in brain activity could not be attributed simply to performance deficits.
Among the participants with fragile X, brain activity decreased in key
areas involved in response inhibition in proportion to fragile X protein
levels. “We are particularly excited to have a marker for this condition
that gives us a tool to begin to query associations across multiple scientific
levels including genetic, brain function and behavior,” said Reiss.
“The study brings neuroscience and psychiatry together in a unique
way.”
The work is part of a comprehensive research program at Stanford directed
by Reiss and devoted to studying fragile X syndrome and other genetic
and neurodevelopmental disorders that affect learning, behavior and development
in children. The research team plans to expand brain imaging research
to test other cognitive and behavioral functions with the disorder, integrating
knowledge gained from genetic, physiological and behavioral studies. They
are recruiting preschoolers, children and adolescents for ongoing studies
to determine, among other things, the timing, amount and type of effective
interventions.
Individuals with fragile X syndrome or other causes of developmental disability
are encouraged to participate in this study. Call (888) 411-2672 or e-mail
vanstone@stanford.edu for more
information.

|
Laughter,
like drugs, tickles brain's reward center (12/10/03)
Pre-implantation
genetic diagnosis offers hope but prompts ethical concerns (3/3/04)
|